TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00515034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
Study: NCT02130778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
Description: infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 500 ml 0.9% saline
Description: infusion of saline
Study: NCT02425384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (motivational website, activity meter)
Description: The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (active video game, activity meter)
Description: The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Control (activity meter)
Description: Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
Study: NCT03992339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
Description: Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Study: NCT00521482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study: NCT04428580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online FBT Training
Description: Therapists will receive online training in Family-Based Treatment (FBT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Webinar FBT Training
Description: Therapists will receive webinar training in Family-Based Treatment (FBT)
Study: NCT02974478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice between meals
Description: orange juice (20% of energy requirement/day)
Study: NCT03204812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT03683433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study: NCT04430738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
Study: NCT02974478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverage between meals
Description: Sugar sweetened beverage (20% of energy requirement/day)
Study: NCT04149379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
Study: NCT03217357

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial stimulation in direct current
Description: tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation in direct current
Description: tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
Study: NCT04213729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Counseling
Description: Standard of care diet counseling provided at clinic visit 1.
Study: NCT04261985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy weight behaviors supported by web-based mobile phone application
Description: Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
Study: NCT00582296

Intervention type: BEHAVIORAL
Intervention: questionnaires, telephone interview, optional blood drawn
Description: Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).

Intervention type: BEHAVIORAL
Intervention: questionnaires, telephone interview and optional blood drawn
Description: Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
Study: NCT05535569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, Paclitaxel
Description: Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
Study: NCT03926130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study: NCT04213729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD LFD
Description: Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
Study: NCT03926130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04213729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD LFD
Description: Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Psychological Support (DPS)
Description: The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
Study: NCT03653338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 depleted leukocytes
Description: Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA depleted leukocytes
Description: Negative selection for CD45RA will be performed on the CliniMACS® depletion device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Sickle Cell Disease Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Sickle Cell Disease Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Sickle Cell Disease Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Sickle Cell Disease Conditioning
Study: NCT02208765

Intervention type: DEVICE
Group type: OTHER
Intervention: Stress Single Photon Emission Computed Tomography
Study: NCT01230411

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: 250 cc of placebo administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg ibuprofen in 250 cc saline administered IV
Study: NCT02427932

Intervention type: DRUG
Intervention: Ampicillin
Description: Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis

Intervention type: DRUG
Intervention: Ampicillin
Description: Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis

Intervention type: DRUG
Intervention: Ampicillin and Gentamicin
Description: Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis

Intervention type: DRUG
Intervention: Gentamicin
Description: Prescribed to non-pregnant participants
Study: NCT02330003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Prefilled Syringe
Description: Fluarix Prefilled Syringe 0.5mL
Study: NCT04863404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask with hybrid-hyrax
Description: Face mask with hybrid-hyrax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask with conventional bonded RME
Description: Face mask with conventional bonded RME
Study: NCT00404248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terameprocol
Description: terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terameprocol
Description: terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
Study: NCT01616147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
Study: NCT01405196

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16
Study: NCT02755350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
Study: NCT03331887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-max CAD endocrown
Description: endocrown used to restore endodontically treated teeth with E-max CAD endocrowns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-max CAd crowns retained with fiber reinforced composite post
Description: fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
Study: NCT03653338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Sickle Cell Disease Conditioning
Study: NCT02498132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitvie Based Therapy
Description: CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
Study: NCT00521482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Thalidomide
Study: NCT04890509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SoC
Description: The SoC will be administered based on local guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: The SoC will be administered based on local guidelines.
Study: NCT03255395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound
Description: Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
Study: NCT03671226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Given questionnaire
Study: NCT02498132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals will be provided with one on one therapy sessions
Study: NCT01854242

Intervention type: OTHER
Intervention: Glycogen Storage Disease type Ia patients
Description: The participants will have one blood draw for this study. The test will be performed on the blood.
Study: NCT00531973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
Study: NCT01453361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Study: NCT03352349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressinum
Description: If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
Study: NCT02095886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176
Study: NCT04156750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02966184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservative free albuterol
Description: Preservative free albuterol for nebulization
Study: NCT00919178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN4 Vaccine Candidate
Description: DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DEN4 Vaccine Placebo
Description: DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.
Study: NCT04024319

Intervention type: PROCEDURE
Intervention: Genicular Nerve Block
Description: 4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
Study: NCT03636087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access cavity preparation
Description: High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access cavity preparation
Description: High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
Study: NCT01972100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy (808nm)
Description: Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo low-level laser therapy